Ratified the Food and Drug Administration "FDA" America, formally , in the second of the month of Nov. , the issuance of a new drug for the treatment of chronic HBV "C", or what is known as the name of a "virus C " , where Egypt is the first in the world in the spread of this disease , and increases the number of people living within about 10 million Egyptian citizen , according to the latest statistics.
The new drug, known as the "Olysio", and owns the American Janssen Pharmaceutical Industries the exclusive right to market , which contains the active ingredient "simeprevir", and exist in the form of tablets obtained by the patient once a day .
It recommended that the administration "FDA" not to be used individually to treat viral hepatitis "C", but should be used alongside drug Alrebavarin and interferon alpha , and confirmed the clinical trials of its effectiveness in the treatment of patients with type I gene .
Was tested the effectiveness and safety of drug "Olysio" through clinical trials , and eating next to drugs Alrebavarin and interferon alpha , and which are used to treat the virus C , and is suitable for patients with liver disease who did not receive treatment at all or for patients who failed them treatment options earlier , as well as people with cystic hepatitis .
And the mechanism of action of the new drug , noted the Food and Drug Administration "FDA" that works by inhibiting the enzyme protease "protease", and invalidate the effectiveness of a protein vital and important , they need a "virus C " Ki doubles and reproduce , which is the third drug ratified and working this mechanism is the same , after the two drugs "Victrelis" and "Incivek", who ratified them in 2011 .
Was sure of the effectiveness and safety of the new drug after undergoing five clinical trials involving 2026 people , were divided into two groups , won the first set on each of the drug "Olysio" beside drug Alrebavarin and Alantrfen Alpha , was awarded the second drug Alrebavarin and Alantrfen thousand only .
The results were very positive , as occurred for the first group in response viral sustainable - any missed Hepatitis C virus detectable in the blood - by 80 % , while the Group has achieved the second did not get the drug "Olysio" ratio of only 50% , after the expiration of the 12-week from the start of clinical trials .
The experiments showed reduced effectiveness of the new drug among people with type gene first "A" malicious viral inflammation of the " C " , and who carry the strain "NS3 Q80K", which is spread most commonly among patients in the United States .
Among the most prominent side effects of the new drug , as demonstrated in clinical trials , when taken together with the drug Alrebavarin and Alantrfen alpha : rash , itching, nausea , and also spread infection allergic skin condition caused by exposure to light , so patients are advised to limit sun exposure and use of protective creams during the treatment period .
The hepatitis "C" is a viral disease the serious hepatic inflammation , and contribute over time to the deterioration of liver function or liver failure , and often do not show any symptoms of the patients with the virus, " C " until it happens obvious damage to the liver , which requires Over several years to become symptomatic .
World filed a "virus C" and cirrhosis within two years, disc one day "for a period of 12 weeks
Posts
0 التعليقات:
Post a Comment